Healthcare / BiotechnologyASX
$0.08
+0.00 (+3.75%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 21%
FCF escenarios
weak_data · normalized FCF $-2.3M · quality 58.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
5/100
F
Piotroski
1/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$14M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-71.9%
↓Gross Margin
90.0%
↑Debt/Equity
N/A
•TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-22.3%
FCF CAGR
—
FCF margin
-1122.3%
FCF / Net income
0.82x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $271707.0 · net income $-3.7M · FCF $-3.0M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $271707.00 | $271707.00 | $177373.00 | $128494.00 | $578171.00 |
| Net Income | $-3.7M | $-3.7M | $-3.0M | $-1.8M | $-1.8M |
| EBITDA | $-3.4M | $-3.4M | $-2.5M | $-1.7M | $-1.7M |
| EPS | -0.03 | -0.03 | -0.02 | -0.01 | -0.01 |
| Gross Margin | 90.0% | 90.0% | 99.6% | 100.0% | 100.0% |
| Operating Margin | -1639.2% | -1639.2% | -1757.0% | -1709.2% | -303.7% |
| Net Margin | -1374.2% | -1374.2% | -1682.9% | -1403.4% | -304.0% |
| Balance Sheet | |||||
| Debt/Equity | — | — | 0.00 | — | — |
| Current Ratio | 6.77 | 6.77 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-3.0M | $-3.0M | $-2.3M | $-1.5M | $-2.0M |
| Returns | |||||
| ROE | -71.9% | -71.9% | -40.2% | — | — |
| Valuation | |||||
| P/B | 1.97 | 1.97 | — | — | — |
| Growth & Yield | |||||
| Revenue Growth | 53.2% | 53.2% | 38.0% | -77.8% | — |
| EPS Growth | -44.3% | -44.3% | -65.4% | -2.4% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-21.0%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.02 → -0.03
Residual
-21.0%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.